Teva Alleges Further Infringement Against Copaxone Patents

Teva Pharmaceutical Industries is seeking to add infringement of three additional patents on its multiple sclerosis drug Copaxone to its claims against Momenta Pharmaceuticals and Sandoz. The amended complaint seeks to include additional patents related to the characterization of Copaxone’s active ingredient, Teva says in a statement this week.
Drug Industry Daily